01 jun: UPDATE: FTC Says Graco Must Sell Illinois Tool's Finishi..
01 jun: Canada's Senate Passes Back-To-Work Bill To End CP Rail ..
01-06-2012 00:14:00

UK Regulator Draft Guidance Recommends Bayer's Xarelto For Blood Clots

Relateret indhold
Relateret debat
19 nov - 
Ingen tvivl om, at den forrentning er i orden for en AA..
19 nov - 
FK@ Den er noteret - men 7,48 % (år til dato) er en flo..
19 nov - 
Bare husk, at AAA-rating ikke altid er det mest passend..

FRANKFURT -(Dow Jones)- The U.K. drug regulator has recommended the use of Xarelto, a drug produced by a unit of Bayer AG (BAYN.XE), to treat blood clots, according to draft final guidance published Friday.

The guidance is likely to result in a recommendation from the National Institute for Health and Clinical Excellence, known as NICE, meaning the U.K. public health-care system will offer the drug and pay for it. The draft guidance is now with consultees, who have the opportunity to appeal against it.

"Bayer Healthcare welcomes this draft final appraisal determination recommendation from NICE because it simplifies the treatment of venous blood clot treatment for physicians and their patients," Bayer spokeswoman Astrid Kranz said.

Earlier, NICE had asked Bayer to provide more information on the drug. The move follows a May 22 approval for Xarelto for stroke prevention and systemic embolism in people with atrial fibrillation.

If the final approval is given, Xarelto, also known as Rivaroxaban, may then be offered as an alternative to injectable anticoagulants such as low-molecular-weight heparin or fondaparinux sodium, overlapped with a vitamin-K antagonist, such as warfarin.

It is estimated that there will be over 46,000 cases of acute deep vein thrombosis, or DVT, in England and Wales during 2012, rising to nearly 50,000 by 2016 due in large part to the aging population, NICE said.

"Xarelto is the first only novel oral anticoagulant offering a unique single drug solution for the treatment of DVT in adults," Kranz said.

On May 24, Bayer confirmed it expects peak sales of Xarelto of above EUR2 billion annually. The drug, which is being co-developed by Bayer and U.S. drug maker Johnson & Johnson (JNJ), is a rival of Boehringer Ingelheim GmbH's Pradaxa.

-By Monica Houston-Waesch, Dow Jones Newswires; +49 69 29 725 504; nikki.houston@dowjones.com

(END) Dow Jones Newswires

May 31, 2012 18:14 ET (22:14 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Roblon opjusterer resultatforventningerne til helåret - NY

27-11-2014 15:45:05
Efter at være blevet forelagt de foreløbige regnskabstal for regnskabsåret 2013/14 har bestyrelsen i Roblon fundet anledning til at justere på forventningerne t..

Jyske Bank sætter F1-rente på 0,3 pct.

27-11-2014 14:24:03
Jyske Bank har fastsat basisrenten på sit populære F1-banklån på 0,3 pct. Det sker, efter at renten på det klassiske F1-realkreditlån er landet på 0,51 pct. ved..

Aktier/middag: Investorerne skifter mening om Royal Unibrew

27-11-2014 11:40:04
Efter et pænt regnskab for tredje kvartal startede Danmarks næststørste bryggeri, Royal Unibrew, dagen med et plus på børsen. Men ved middagstid er gassen gået ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestjysk Bank Q3: Nedskrivninger i landbruget giver underskud
2
SAS har succes med luksus-rute til USA - avis
3
Aktier/middag: Investorerne skifter mening om Royal Unibrew
4
Lundbeck: Analytikerne skærer halvanden mia. af forventningerne
5
USA: Amerikansk aktiemarked lukket på grund af Thanksgiving

Relaterede aktiekurser

Johnson & Johnson 107,21 0,5% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. november 2014 07:53:34
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141127.2 - EUROWEB6 - 2014-11-28 07:53:34 - 2014-11-28 07:53:34 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x